Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
As of today (2026-08-16), Sagimet Biosciences's share price is €8.86.
Sagimet Biosciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.99. Hence, Sagimet Biosciences's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for Sagimet Biosciences's Price-to-Free-Cash-Flow or its related term are showing as below:
STU:0O2's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 28.455 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was -8.50% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was -22.80% per year.
During the past 7 years, Sagimet Biosciences's highest 3-Year average Free Cash Flow per Share Growth Rate was -8.50% per year. The lowest was -69.10% per year. And the median was -21.90% per year.
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Sagimet Biosciences Price-to-Free-Cash-Flow Related Terms
Sagimet Biosciences Price-to-Free-Cash-Flow Historical Data
* Premium members only.
The historical data trend for Sagimet Biosciences's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:0O2 vs CABA, OVID, QTTB: Price-to-Free-Cash-Flow Comparison
For the Biotechnology subindustry, Sagimet Biosciences's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sagimet Biosciences Price-to-Free-Cash-Flow vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Sagimet Biosciences's Price-to-Free-Cash-Flow falls into.
Sagimet Biosciences's Share Price of today is €8.86. Sagimet Biosciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.99.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Is Sagimet Biosciences (STU:0O2) Overvalued in 2026?
Based on GuruFocus' analysis, Sagimet Biosciences stock appears to be overvalued.
The current stock price of €8.86 is trading 55.7% above its estimated GF Value™ of €5.69.
GuruFocus considers Sagimet Biosciences to be Significantly Overvalued.
Key valuation signals for STU:0O2:
Price-to-Free-Cash-Flow: N/A
GF Value™: €5.69 vs. price of €8.86 (55.7% above fair value)
No single metric tells the full story. See the STU:0O2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
33GF Score
Get the complete analysis for STU:0O2
Price-to-Free-Cash-Flow is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0O2 has been successfully added to your 
